Table 4.
Summary of the literature on fibroma‐associated hypercalcemia in nonpregnant women
| Bilici et al. 22 | Dagdelen et al. 23 | Herring et al. 24 | Garcha et al. 25 | |
|---|---|---|---|---|
| Age (years) | 45 | 48 | 49 | 79 |
| Clinical presentation | Anorexia, nausea, vomiting, constipation | Uncontrolled type 2 diabetes mellitus, inguinal pain, menometrorrhagia | Lethargy | Altered mental status, falls, acute renal failure |
| Discovery of fibroma | Gynecologic examination + CT scan | CT scan | Ultrasound + CT scan | CT scan |
| Surgery | TAH‐BSO | TAH‐BSO | TAH‐BSO | TAH‐BSO |
| Maximal Ca level (mmol/L) | 4 (NR 2.1–2.63) | 3 (NR N/A) | 3.37 (NR 2.1–2.6) | 4.25 (NR N/A) |
| PTH (pmol/L) | Undetectable | Undetectable | 0.3 (NR 0.7–5.7) | 1.4 (NR 1.6–6.9) |
| PTHrP (pmol/L) | 1.4 (NR < 1.3) | 2.5 (NR < 1.3) | 4.6 (NR < 1.8) | 40 (NR 14–27) |
| Treatment | Hydration, calcitonin, furosemide, pamidronate | Hydration, furosemide | Zoledronic acid | Hydration, furosemide |
| Fibroma characteristics | 6 cm, intramural | 6.9 cm, intramural | 7.5 cm, uncertain malignant potential, histological proof of PTHrP expression | Small and multiple |
Ca, calcium; N/A, not available; NR, normal range; PTH, parathyroid hormone; PTHrP, parathyroid hormone‐related protein; TAH‐BSO, total abdominal hysterectomy and bilateral salpingo‐oophorectomy.